Glutamine Deprivation Induces Abortive S-Phase Rescued by Deoxyribonucleotides in K-Ras Transformed Fibroblasts by Gaglio, Daniela et al.
Glutamine Deprivation Induces Abortive S-Phase
Rescued by Deoxyribonucleotides in K-Ras Transformed
Fibroblasts
Daniela Gaglio, Chiara Soldati, Marco Vanoni, Lilia Alberghina, Ferdinando Chiaradonna*
Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy
Abstract
Background: Oncogene activation plays a role in metabolic reprogramming of cancer cells. We have previously shown that
K-ras transformed fibroblasts have a stronger dependence on glycolysis and a reduced oxidative phosphorylation ability as
compared to their normal counterparts. Another metabolic adaptation of cancer cells, that has long been established, is
their propensity to exhibit increased glutamine consumption, although the effects induced by glutamine deprivation on
cancer cells are still controversial.
Methodology and Principal Findings: Here, by using nutritional perturbations and molecular physiology, we show that
reduction or complete depletion of glutamine availability in K-ras transformed fibroblasts causes a strong decrease of
proliferation ability and a slower re-entry of synchronized cells into the cell cycle. The reduced proliferation is accompanied
by sustained expression of cyclin D and E, abortive S phase entrance and is dependent on Ras signalling deregulation, since
it is rescued by expression of a dominant negative guanine nucleotide exchange factor. The growth potential of
transformed cells as well as the ability to execute the G1 to S transition is restored by adding the four deoxyribonucleotides,
indicating that the arrest of proliferation of K-ras transformed cells induced by glutamine depletion is largely due to a
reduced supply of DNA in the presence of signalling pathways promoting G1 to S transition.
Conclusions and Significance: Our results suggest that the differential effects of glutamine and glucose on cell viability are
not a property of the transformed phenotype per se, but rather depend on the specific pathway being activated in
transformation. For instance, myc-overexpressing cells have been reported to die under glutamine depletion and not under
glucose shortage, while the opposite holds for ras-transformed fibroblasts as shown in this paper. These different responses
of transformed cells to nutritional stress should be taken into account when designing anti-cancer therapies that aim to
exploit metabolic differences between normal and transformed cells.
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Introduction
Increasing attention has been given in recent years to the
connection between metabolic alterations and cancer [1]. Under
aerobic conditions, normal cells use oxidative phosphorylation as a
predominant source for ATP generation. In sharp contrast to
normal cells,a commonfeature of most cancer cellsis a majoruse of
glycolysis to produce ATP [2–6]. The onset of a glycolytic
phenotype and/or impaired mitochondrial function [7–9] in cancer
cells have been reported to derive from several mechanisms,
including adaptation to hypoxia, oncogene activation or loss of anti-
oncogene and the consequences of glucose deprivation have been
extensively described in several cancer cells and tissues, for a review
see [10]. Another metabolic adaptation of cancer cells, that has long
been established, is their propensity to exhibit increased glutamine
consumption,althoughthe effectsinducedbyglutaminedeprivation
on cancer cells are still controversial, mostly because of the diverse
cellular processes in which glutamine is involved. Indeed, as a
metabolic precursor glutamine is required for protein, RNA and
DNA biosynthesis, and through glutaminolysis, participates in
energy production and cellular redox homeostasis, especially to
glutathione synthesis [11]. Accordingly, different Authors assigned
to glutamine a role in: growth and survival of several cell lines such
as fibroblasts, enterocytes, and lymphocytes through modulation of
the signal transduction pathway(s) and the cell cycle machinery;
suppression of apoptosis through a modulation of the ability to
respond to stress; maintenance of metabolic processes such as TCA
cycle, fatty acid synthesis controlling the supply of essential
intermediates. Therefore, understanding the effects of glutamine
deprivation is necessary to obtain a more complete appreciation of
changes in tumor metabolism [11].
NIH3T3 cells are a genetically well defined immortalized cell
line that has long established as a model parental cell line for the
study of cell transformation [12,13]. Like some other cancer cells,
K-ras transformed fibroblasts exhibit a high rate of glucose
consumption associated with mitochondrial dysfunction and
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and unpublished results, events often associated with cancer
phenotype. As a result, K-ras transformed NIH3T3 cells are
remarkably sensitive to glucose deprivation [15], a condition in
which they stop growth and die. Transformation-related pheno-
types of K-ras transformed cell lines can be rescued by expression of
a dominant-negativeguaninenucleotideexchangefactor(GEF-DN)
[15–17].
Here we compared the physiological response to glutamine
limitation of normal NIH3T3 mouse fibroblasts (normal cells);
NIH3T3 cells transformed by an activated form of the K-ras
oncogene (transformed cells) and K-ras transformed NIH3T3
fibroblasts reverted by expression of a GEF-DN (reverted cells).
Glutamine deprivation strongly decreases proliferation of trans-
formed cells, while having little, if any, effect on normal and
reverted lines. No glutamine depletion-dependent reduction in
overall protein synthesis or in ATP level was observed in
transformed cells compared to their isogenic counterpart. Reduced
proliferation of transformed cells was accompanied by sustained
accumulation of cyclin D, E and A and abortive S phase entrance.
The proliferation defect of transformed cells could be restored by
adding the four deoxyribonucleotides (but not TCA cycle
intermediates), indicating that the arrest of growth of K-ras
transformed cells induced by glutamine depletion is largely due
to a reduced supply of DNA precursors in the presence of active
signaling pathways promoting entrance into S phase.
Results
Reduced proliferation of K-ras transformed fibroblasts in
media containing low initial glutamine concentration is
associated to an increased fraction of cells in S-phase
Glutamine is an important substrate for several cellular
processes. We tested whether lowering initial glutamine concen-
tration in culture medium elicited differential effects on the
proliferation of transformed cells as compared to normal cells.
Asynchronous normal and transformed cell lines were cultured in
normal growth medium (4 mM glutamine), in an intermediate
medium (1 mM glutamine) and in a low glutamine medium
(0.5 mM glutamine). These concentrations were chosen consider-
ing glutamine levels normally used in cell culture (between 4 and
2 mM) as well as that determined in human plasma (0.6 mM). All
media were supplemented with 25 mM glucose. Cells were
followed for at least 144 hours, that is, from the moment of
seeding to when they either reached confluence, started to grow in
multi-strata or to die. All experiments reported in this and the
following paragraphs refer to the above-mentioned experimental
setup.
Normal cells stopped growth after 72 hours, regardless of
glutamine concentration. At later time, cell number started to
decrease (Fig. 1A–C, X symbol). Concurrently, apoptotic
phenotypes - including the presence of floating, dead cells
(Figure 1D, upper panels) - were observed in normal cells
regardless of glutamine concentration, possibly because of
prolonged contact inhibition. In normal and intermediate
glutamine medium, transformed cells continued to proliferate
and reached a much higher cell density than normal cells, but
proliferation advantage of transformed cells was almost completely
lost when they were grown in low glutamine medium as scored by
both cell counting (Fig. 1C, ca 1,1610
6, 0,9610
6 and 0,4610
6 at
144 hours respectively for cells grown in normal, intermediate and
low glutamine concentration) and direct microscopic observation
(Fig. 1D, compare lower left and lower right bottom panels).
Regardless of glutamine concentration, little, if any, floating, dead
cells were observed in transformed cells (Fig. 1D). A similar loss of
proliferation potential was observed in the human HEP3B and
HCT116 cancer cell lines when cultured in 0.5 mM glutamine
(data not shown), suggesting that the inhibition of cell proliferation
by glutamine reduction is a general feature of transformed cells.
As previously reported [15], balanced exponential phase was
very short, since despite exponential increase in cell number, the
fraction of G1 cells started to increase as early as at 48 hours after
the beginning of the experiment, the more so for normal cells
(Fig. 1E). Remarkably, transformed cells grown in low glutamine
medium retained quite a large fraction of S and G2/M phase cells
even at the 72 or 96 hours time points, i.e., when the increase in
cell number had stopped. Indeed, after 72 hours of growth,
transformed cells had a very similar fraction of cells in the S+G2M
phases regardless of glutamine concentration, while a significant
difference could be observed compared to normal cells. Quanti-
fication of the amount of BrdU incorporated into DNA is taken to
be more precise than Propidium Iodide to evaluate S-phase cells,
therefore DNA synthesis was then analyzed by BrdU incorpora-
tion (30 min pulse) detected by immunofluorescence using a BrdU
specific antibody and BrdU-positive cells were counted (Figure 1F).
While the fraction of normal BrdU-incorporating cells steadily
decreased from 48 hours, arriving to around 1% after 96–
144 hours of growth, the fraction of transformed BrdU-incorpo-
rating cells at 96–144 hours of growth remained high, the more so
in cells growing in media supplemented with 0.5 mM glutamine.
Compare for instance normal and transformed cells grown for
96 hours in media supplemented with 0.5 mM glutamine: normal
and transformed cells have reached the same, maximal density,
but the fraction of BrdU-incorporating cells is almost 0% for
normal cells and at least 15% in transformed cells. This value
remains constant until the end of the experiment and is essentially
the same for cells grown in 4 mM or 0.5 mM glutamine, despite
the large difference in proliferation.
Glutamine uptake was indirectly measured by assaying residual
glutamine in the medium (Figure S1A and B). At each glutamine
availability, normal and transformed cells consumed glutamine at
the same rate. Remarkably, glutamine uptake was much faster in
cells grown at low initial glutamine concentration (Figure S1B).
We could show that at least 20% of initial glutamine (i.e. ca
0.8 mM) is still present at 96 hours in cells grown at 4 mM initial
glutamine concentration, i.e. when normal cells have stopped to
proliferate (Figure S1A). In normal and transformed cells grown in
low initial glutamine concentration, on the contrary, no residual
glutamine is present at 96 hours. Transformed cells stopped
growth afterwards, indicating that glutamine acts as a limiting
nutrient under these conditions. We could neither detect any
glutamine in Newborn Calf Serum nor see any difference in
growth when growth media were supplemented with dialyzed
serum (data not shown).
When initial plating density was lowered to 2000 cells/cm
2
(compared to our standard plating density of 3000 cells/cm
2) the
same phenotypes reported above were observed, but with a
24 hour delay, consistently with the notion that glutamine is not
the factor limiting proliferation of normal cells in our experimental
set-up (Figure S2A, C and D).
In transformed cells sustained S-phase in low glutamine
is associated with prolonged expression of cyclin D, E
and A, enhanced pRb phosphorylation, decreased level
and cytoplasmic localization of p27
Kip1
Oncogenic Ras activation is known to promote the G1 to S
progression [15–18,19]. Results reported in the previous para-
Glutamine Oncogenic Kras Cells
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e4715Figure 1. Glutamine shortage induces cell proliferation arrest and S-phase accumulation in oncogenic K-ras transformed
fibroblasts. Normal (X) and transformed (&) cell lines were plated at 3000 cells/cm
2 in 6-well plates in normal medium. Culture medium was
replaced after 24 hours with a normal medium 24 mM glutamine- (A), an intermediate medium 21 mM glutamine- (B) and a low medium 20.5 mM
glutamine- (C) and the cells were collected and counted at indicate time. (D) Morphological analysis of normal cells (upper images) and transformed
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medium retain a large fraction of cells in S-phase while
proliferation is stopped suggesting that in transformed cells
glutamine depletion does not efficiently shut-down the G1 to S.
It was therefore of interest to analyze both in normal and in
transformed cells modulation by glutamine of relevant parameters,
such as level, phosphorylation state and sub-cellular localization of
proteins involved in the G1 to S transition.
Transcription of genes required for the onset of S-phase in
mammalian cells is induced by the E2F/DP transcription factors,
whose activity in early G1 cells is down-regulated by the pRb
protein. Release of inhibition by pRb requires its phosphorylation
by upstream cyclin dependent kinase complexes, namely Cdk4/
cyclin D and Cdk2/cyclin E [20]. Notably both Cdk2 and Cdk4
kinase complexes phosphorylate, during the G1 to S transition,
pRb protein on Ser 795. Several Authors have considered this
phosphorylation as a readout of Cdks activity. D-type and E-type
cyclin/Cdk complexes are regulated by cyclin binding, by
phosphorylation and by two families of Cdk inhibitors: the
INK4 family, that acts specifically on Cdk4, and the KIP family,
that comprises p21
Cip1, p27
Kip1 and p57
Kip2 acting both on Cdk4
and Cdk2 [21]. Besides, p21
Cip1 and p27
Kip1 also facilitate
assembly and activation of cyclin D/Cdk4 in early G1 [21,22].
pRb phosphorylated on Ser795 was detected using a phospho-
specific antibody raised against pRb
Ser795 and that does not cross
react with unphosphorylated pRb. In normal cells, and regardless
of initial glutamine concentration, Ser795-phosphorylated pRb -
i.e. the form that monitors the activity of both Cdk4 and Cdk2
kinases - decreases as cells approach and reach confluence
(Figure 2, panels A and B4). Concurrently, drops in cyclin D1,
E and A were observed, their level being at - or below - the
detection limit at the 96 hours time point (Figure 2, panels A
through B3). A decrease in Cdk2 and a more permanent
expression of Cdk4 was observed during the time course of the
experiment (Figure S3). Moreover, as shown in Figure 3A, 3C and
S4B and S4C, in normal cells grown in media supplemented with
the three initial glutamine concentrations, the expression of the
p27
Kip1 and p21
Cip1 proteins showed a time-dependent increase
for p27
Kip1 and a decrease for p21
Cip1 (independent of the initial
glutamine concentration).
The inhibitory function of p27
Kip1 is regulated not only through
synthesis and degradation, but also by sub-cellular localization.
Indeed, cytoplasmic p27
Kip1 has been detected in about 40% of
primary human breast cancers in conjunction with Akt activation
and is associated with poor patient prognosis and reduced Cdks
inhibitory activity [23–25]. In normal cells, grown in 4 and
0.5 mM GLN, associated with the time-dependent increase of
p27
Kip1, we observed that p27
Kip1 staining remained diffuse at
early time points (24–48 hours - proliferating cells -, Figure 3,
panels E, F, G and H), and strongly accumulated in the nucleus at
later time points (72–96 hours- arrested cells – Figure 3, panels E,
F, G and H). Increased p27
Kip1 expression and nuclear
localization well correlate with the decrease of S-phase cells and
of pRb
Ser795 phosphorylation observed during the time course of
the experiment.
For transformed cells the pattern was very different. In cells
grown in media supplemented with 4 mM glutamine, Cyclin D, A
and E as well as phospho-Rb decreased only to about 50% of the
level present at 24 hours (Figure 2, panels C through D4), while
Cyclin D1 decreased significantly more at intermediate and low
glutamine concentrations. Differently to the pattern observed in
normal cells, transformed cells showed fairly constant Cdk4, Cdk2
and p21
Cip1 levels during the time course of the experiment
(Figure S3 and S4C), and no increase in the level of p27
Kip1
(Figure 3D): indeed p27
Kip1 was barely detectable in cells grown in
low glutamine, at the last time point (96 h) (Figure 3B and D).
Immunofluorescence staining, in both low and high glutamine
availability, revealed that in transformed cells a large fraction of
p27
Kip1 remained cytoplasmic, in contrast to the situation
observed in normal cells where the majority of this Cki is nuclear
at later time points (compare Figure 3 I–N, for transformed cells
with Figure 3E–H, for normal cells). However, double immuno-
fluorescence staining performed by using anti-BrdU and anti-
p27
Kip1 specific antibodies, to score p27
Kip1 localization in normal
and transformed BrdU positive cells, showed that almost all the
BrdU positive cells had a nucleo/cytoplasmic localization of
p27
Kip1 protein (Figure S4A and B).
Down-regulation of Ras signalling by a dominant-
negative Ras-specific GEF reverts low glutamine-
dependent phenotype in K-ras transformed fibroblasts
Overexpression of a dominant negative Ras-specific GEF
protein has been reported to phenotypically revert several
phenotypes in K-ras transformed murine fibroblasts, including
Ras-GTP level, morphology, anchorage independent growth,
reduction of Ras-dependent tumor formation in nude mice,
glucose dependence and mitochondrial dysfunction [15–17]. As
shown in Figure 4, K-ras transformed cells expressing the
dominant-negative GEF showed a complete reversion of all the
phenotypes observed in transformed cells grown in all the three
glutamine conditions. Indeed, as shown in Figure 4A and B,
reverted cells accumulated in G1, decreased the fraction of BrdU
positive cells, reduced their proliferation ability (data not shown) in
time-dependent manner, as observed in normal cells. Such results
were totally confirmed by protein expression analysis (Figure 4D)
in which a decrease of cyclin D1, E, A and pRb phosphorylation
and an increase of p27
Kip1 in a time-dependent and glutamine-
independent manner were observed. Finally, cellular localization
analysis of p27
Kip1 protein showed a similar behaviour to that
observed in normal cells (Figure 4E, F, G and H). Taken together,
these data support the notion that the exquisite sensitivity of
transformed cells to glutamine depletion is due to constitutive
expression of oncogenic K-ras.
Glutamine reduction does not substantially interfere with
RNA synthesis, protein synthesis and energy metabolism
Amino acid deprivation leads to a fall in the rate of RNA and
protein synthesis and consequently to a reduction of total cellular
protein content [26,27]. Such effect could be even more significant
upon depletion of glutamine - the more abundant amino acid in
tissues, body fluids and cell culture medium - because of its
involvement in the biosynthesis of several amino acids (glutamate,
aspartate, arginine, alanine) as well as in energy production [28–
30] and nucleotide biosynthesis [31].
cells (lower images) cultured in 4 mM glutamine (left images) and 0.5 mM glutamine (right images) at 96 hours. Cells were observed at phase-
contrast microscopy. Exponentially growing normal and transformed cells were incubated for increasing periods of time (24, 48, 72, 96 and 144 h) in
medium containing 4 mM and 0.5 mM glutamine, then harvested, counted and subjected to FACS analysis after staining with propidium iodide (E),
or pulsed 30 minutes with BrdU and then analyzed by fluorescence microscopy using an anti-BrdU specific antibody (F). Results are the mean of at
least triplicate determinations with standard deviations indicated. For BrdU staining were analyzed at least 200 cells for each sample.
doi:10.1371/journal.pone.0004715.g001
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total RNA and protein accumulation. To this end, the time course
of average of RNA and protein content per cell was analyzed. The
average RNA content of normal and transformed cells, regardless
of glutamine availability, slightly decreased along the time course
of the experiment. The time course decrease in RNA content of
transformed cells growing in low glutamine, was somehow more
sizeable as compared to that observed in normal cells suggesting
that glutamine reduction may hamper biosynthesis of nucleotides
and hence the synthesis of stable RNA (Figure 5A and B).
Figure 2. Expression of proteins involved in the G1 to S transition in normal and transformed cells. For the protein expression analysis
normal cells (A) and transformed cells (C) grown in media containing 4 mM glutamine, 1 mM glutamine and 0.5 mM glutamine were collected at
appropriate time points and 40 mg of proteins from the total cellular extract were subjected to SDS-PAGE followed by Western blotting with
appropriate antibodies. One of at least three independent experiments is shown. (B1–B4 and D1–D4) Relative quantitative analysis of protein levels
after Western blot film acquisition by scanner and densitometry analysis using Image J program. The densitometry values obtained for each protein
were normalized by using the values of the corresponding vinculin and were plotted considering the densitometry value obtained for the sample
24 hours/4 mM glutamine as equal 1. Results are the mean of at least triplicate determinations with SD indicated.
doi:10.1371/journal.pone.0004715.g002
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regardless of glutamine concentration, a small decrease in protein
content was observed in normal cells (Figure 5C and D). On the
contrary, the protein content of transformed cells showed a
substantial increase with time. No major quali-quantitative
changes could be observed by Comassie staining of SDS-PAGE
gels, at least within the limited resolution of this technique (Figure
S5). These results are summarized in panels E and F, showing that
in 4 mM glutamine, time-dependent changes in the RNA/protein
ratio for normal and transformed cells are very similar, while
transformed cells show a more detectable decrease of this
parameter when grown under limiting glutamine.
Glutamine is an oxidizable fuel, which enters the TCA cycle as
a-ketoglutarate, by reactions catalyzed by aspartate amino
Figure 4. The GEF-DN protein completely reverts the phenotype induced by oncogenic K-ras expression in glutamine shortage. Cell
cycle distribution (A), S-phase cell population (B), time-course of the expression of proteins involved in the G1 to S transition and pRb
phosphorylation in Serine795 (C), relative quantitative analysis for p27
kip1 protein (D) and p27
kip1 cellular localization (E, F, G and H) in reverted cells
grown in diverse initial glutamine availability as differently indicate in the Figure. The experiments were performed as indicated in previous figures.
The averages of at least three independent experiments are presented in A, B, D, G and H with errors bars indicating SD. Bars, 20 mm.
doi:10.1371/journal.pone.0004715.g004
Figure 3. Expression and localization of p27
kip1 in normal and transformed cells. For p27
kip1 expression analysis normal cells (A) and
transformed cells (B) grown in media containing 4 mM glutamine, 1 mM glutamine and 0.5 mM glutamine were collected at appropriate time points
and 40 mg of proteins from the total cellular extract were subjected to SDS-PAGE followed by Western blotting with p27
kip1 specific antibody. One of
at least three independent experiments is shown. Relative quantitative analysis of p27
kip1 protein levels after Western blot film acquisition by scanner
and densitometry analysis using Image J program, as described in Figure 2, in normal cells (C) and transformed cells (D). p27
kip1 cellular localization in
normal (E, F, G and H), and transformed (I, L M and N) cell lines was analyzed by immunofluorescence staining for p27
kip1 (red staining), after 24 and
96 hours of growth in media supplemented with either 4 mM glutamine (left pictures) or 0.5 mM glutamine (right pictures). Nuclei were visualized by
DAPI staining (Blue staining). The pictures are the result of a merge between the two single images acquired. At least 200 cells were scored for each
sample. The averages of three independent experiments are presented in G, H, M and N with errors bars indicating SD. Bars, 20 mm.
doi:10.1371/journal.pone.0004715.g003
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PLoS ONE | www.plosone.org 7 March 2009 | Volume 4 | Issue 3 | e4715Figure 5. Analysis of some glutamine-dependent cellular processes in normal and transformed cells. Amount of the total RNA, proteins
and ratio RNA/protein for single cell calculated after spectrophotometric determination of total RNA extracted by using TRIzol solution and different
lysis buffer (protein) of normal and transformed cells grown in 4 mM glutamine (A, C and E), and 0.5 mM glutamine (B, D and F) along a time course.
Normal (G) and transformed (H) cell lines were plated at 3000 cells/cm
2 in 6-well plates in normal medium. Culture medium was replaced after
24 hours with a normal medium 24 mM glutamine- (e), a low medium 20.5 mM glutamine- (%), a medium with 0.5 mM glutamine and 2 mM
pyruvate (n) and a medium with 0.5 mM glutamine and 2 mM malate (#) and then the cells were collected and counted at indicate time. ATP
content in the two cell lines was measured using a luciferin-luciferase assay along the time course in 4 mM (I), 1 mM (L) and 0.5 mM glutamine
availability (M). ATP concentrations were calibrated against ATP standards and expressed as nanomoles per 10.000 cells. In all the experiments the
averages of at least three independent experiments are presented with errors bars indicating SD.
doi:10.1371/journal.pone.0004715.g005
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Accordingly it has been reported that glutamine depletion could
cause a deficiency of this cycle [34,35]. Supplementing the growth
medium (containing 0.5 mM glutamine) with either 2 mM
pyruvate, which can enter the TCA cycle mainly through its
conversion in Acetyl-CoA or 2 mM malate which can enter the
TCA cycle by conversion into oxaloacetate and/or furnish
reducing equivalents by malic enzyme activity, in the last steps
of glutaminolysis, did not rescue the proliferation defect caused by
low glutamine in transformed cells (Figure 5G and H). Indeed the
three growth curves, corresponding to 0.5 mM glutamine alone or
plus pyruvate or malate were completely superimposed for both
cell lines.
The ATP level was measured in normal and transformed cells
(24, 48, 72 and 96 hours in 4, 1 and 0.5 mM glutamine, Figure 5I,
L and M). ATP decreased in both cell lines along the time-course
of the experiment. In all cases substantial residual ATP was
present even at the latest assayed time, however normal cells
showed a more pronounced drop in ATP (20%, 41% and 38% for
cells grown in media supplemented with 4 mM, 1 mM and
0.5 mM initial glutamine, respectively) than transformed cells (5%,
25% and 18% for cells grown in media supplemented with 4 mM,
1 mM and 0.5 mM initial glutamine, respectively). The same
analyses performed on reverted cells confirmed a behavior similar
to that observed in normal cells (data not shown). These results
rule out the possibility that glutamine effects on transformed cells
are due to energy depletion.
Addition of deoxyribonucleotide triphosphates rescues
the abortive S-phase entrance induced by low or full
absence of glutamine in K-ras transformed fibroblasts
Results reported above indicate that in transformed cells energy
metabolism under limiting glutamine concentration is not heavily
unbalanced, since these cells have normal ATP and protein levels,
and do not benefit from increasing fuel supply to the TCA cycle.
On the other hand under limiting glutamine conditions,
transformed fibroblasts fail to down-regulate the machinery
responsible for the G1 to S transition, as evidenced by sustained
accumulation of S-phase cyclins, low levels and larger cytoplasmic
localization of p27
kip1 and ensuing sustained phosphorylation of
pRb. Nevertheless transformed cells are unable to proceed with
proliferation although maintaining a fairly high level of S-phase
cells. Since glutamine is an important intermediate in purine and
pyrimidine biosynthesis, glutamine exhaustion could deplete
intracellular nucleotide pools, bringing in turn to a failure in the
execution of a normal cell cycle [31,36]. To test this hypothesis, we
examined whether adding deoxyribonucleotides (using a concen-
tration that has been shown to not interfere with proliferation of
several cell lines in vitro) [37] could affect proliferation of normal
and transformed cell lines. The presence of 10 mM dNTPs (dATP,
dGTP, dTTP and dCTP) had no effect on growth of both normal
and transformed cells in media supplemented with 4 mM
glutamine (Figure S6, panels A and B) and on growth of normal
cells in media supplemented with 0.5 mM glutamine (Figure 6A).
On the contrary, addition of dNTPs sustained further growth of
transformed cells, whether added once (at time 0 h) or twice (at
time 0 h and 48 h) (compare squares, triangles and circles in
Figure 6B). However, deoxyribonucleotides failed to revert the low
glutamine-induced proliferation defect when added later, i.e. at
72 hours (data not shown). These results indicate that sustained
supply of deoxyribonucleotides relieves glutamine dependence of
proliferation in transformed cells.
To better analyze the G1 to S transition, cells grown in medium
containing 4 mM glutamine were synchronized by serum
starvation for 24 hours. As expected, transformed cells did not
block in G0/G1 as effectively as normal cells (Figure 6 C through
F), being 89% for normal and 78% for transformed, the
percentage of cells with prereplicative DNA content as determined
by bi-parametric BrdU/PI staining. The cell cycle block was
released by adding 10% serum in media containing either 4 mM
glutamine, 0.5 mM glutamine or 0.5 mM glutamine plus 10 mM
dNTPs, and collected at indicated time points (8, 10, 12, 14, 16, 18
and 20 h). The time-course of transit through the cell cycle phases
was then followed. Normal cells showed equal kinetics of re-entry
into cell cycle regardless of glutamine concentration. The fraction
of G0/G1 cells reached a minimum 14–16 hours after serum
stimulation (panel E), while S-phase (panel G) and G2/M phase
(panel I) peaked at 14 and 18 hours respectively. Transformed
cells reproducibly anticipated their entry into S-phase as compared
to normal cells (8 h vs. 10 h, panels G and H), regardless of
glutamine concentration. The peak in S-phase (panel H) and G2/
M phase (panel L) was also anticipated, but only in cells stimulated
in media containing 4 mM glutamine (black bars) or 0.5 glutamine
plus 10 mM dNTPs (white bars), but not in cells stimulated in
media containing 0.5 mM glutamine (grey bars).
We next investigated whether nucleotide addition was effective
also on cells released from a serum starvation block in complete
absence of glutamine using the same protocol used in Figure 6.
Cell cycle re-entry of normal cells was unaffected by release in
0 mM glutamine, regardless of the presence of nucleotides
(Figure 7, panels A, C and E). In transformed cells, release in
the absence of glutamine delayed S phase entrance of 2 hours
(Figure 7, panels B and D) and delayed reaching of the S-phase
peak of further 2 hours (Figure 7, panel D, asterisks). Addition of
10 mM dNTPs to transformed cells released in 0 glutamine (white
bars) rescued the delay in S phase entrance, the delay in reaching
the S phase peak, but did not rescue the delay in traversing the
G2/M phase (panel F, compare black and white bars).
These data indicate that the major effect of glutamine limitation
in transformed cells is to increase the length of S-phase, the peak of
S-phase cells being reached 2 hours later in low glutamine
(Figure 6 H, peaks indicated by asterisks) and 4 hours later in
full absence of glutamine (Figure 7 D, peaks indicated by asterisks):
this function of glutamine can be preserved by dNTPs. Complete
glutamine depletion severely slows down transit through G2/M,
regardless of dNTPs supply (Figure 7 F), indicating a distinct role
of glutamine in this cell cycle phase.
Response of selected signalling pathways to glutamine
availability and effect of rapamycin treatment on
proliferation ability in normal and transformed cells
In different transformed cell lines glutamine or other amino
acids shortage has been reported to induce accumulation of cells in
G0/G1 and/or an increase in doubling time and a decrease in
maximal reached cell density [36,38,39]. Such anti-proliferative
effects, most likely mediated by the TOR pathway [40,41], have
been associated either to a general decrease of mRNA translation
and/or protein biosynthesis or to a specific decrease/increase of
expression of both positive and negative regulators of cell cycle, as
observed in cells deprived of arginine (decrease of Cdk4) [42], in
cells deprived of hystidine (increase of p21
waf1 and p27
kip1)o r
methionine (increase of p21
waf1) [43,44]. In non-transformed cells,
upstream activators such as PI3K/Akt and Ras/Raf/Erk and
upstream inhibitors such as the phosphates PTEN and the AMP
kinase properly control activation of TOR pathway. In trans-
formed cells, the TOR pathway is deregulated through several
pathways, among which a primary role is assigned to oncogenic
Glutamine Oncogenic Kras Cells
PLoS ONE | www.plosone.org 9 March 2009 | Volume 4 | Issue 3 | e4715Figure 6. Proliferation analysis of normal and transformed cells adding in culture medium the four dNTPs. Normal (A) and transformed
(B) cell lines were plated as previously described. Culture medium was replaced after 24 hours (indicated as 0 h) with a normal medium 24m M
glutamine- (e), a low medium 20.5 mM glutamine- (%), a medium with 0.5 mM glutamine and 10 mM dNTPs -ATP, GTP, TTP and CTP- (n) and a
medium with 0.5 mM glutamine and 10 mM dNTPs in which the dNTPs were added at 0 and 48 hours (#), then the cells were collected and counted
at indicate time. Normal (left panels) and transformed (right panels) cells, synchronized by 24 hours serum starvation, were released in a medium
containing 10% serum, 4 mM or 0.5 mM glutamine, dNTPs and BrdU for continuous DNA labeling. At indicate time points the cells were collected
and stained with propidium iodide and anti-BrdU specific antibody and analyzed by flow cytometry. Representative cytograms, obtained for
asynchronous and 0 hours (time 0) time point samples respectively, plotting BrdU content (labeled cells) vs. PI staining (DNA content) (Figure 6 C -
normal cells - and D - transformed cells -). Red color in the plot represents the S-phase cells. The percentages of cells in G1 (panels E and F), S (panels
G and H) and G2/M (panels I and L), phase of normal (left panels) and transformed (right panels) cells released in 4 mM and 0.5 mM glutamine alone
or plus dNTPs obtained by bi-parametric analysis as shown above, are represented. The asterisks indicate the S or G2/M phase peaks identified in both
glutamine availability. The error bars correspond to standard deviations of triplicate analysis.
doi:10.1371/journal.pone.0004715.g006
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TOR pathways (PI3K and ERK) [45,46].
To investigate the role of signal transduction in the response of
normal and transformed cells to glutamine shortage, we analyzed the
level of expression and activation of two main regulators of the TOR
pathway, Akt and AMPK, as well as the level of expression and
activation of a downstream TOR target p70 S6 kinase (S6K). As
showninFigure8A,innormalcells,theactivatedformofAkt(probed
with an anti-phosphoserine 473 antibody) decreases as a function of
time and regardless initial glutamine concentration. In transformed
cells the level of phosphorylated Akt is always very significant, being
marginally higher at initial time points and not reduced as a function
of time nor effected by glutamine concentration.
As previously reported, TOR protein is also controlled through
AMPK, which is activated by a drop in the ATP/ADP ratio with
ensuing AMP accumulation that leads to a signaling bringing to
different cellular responses as well as to cell cycle arrest [47]. Our
Western blot experiments to analyze the AMPK activation status
in cells grown in different glutamine availability, showed that in
correlation with a drop of ATP levels in both cell lines, only in
normal cells, in which the ATP decrease was greater (see Figure 5I,
L and M), a reliable and glutamine-dependent increase of AMPK
activation was observed (Figure 8B, 1 mM and 0.5 mM glutamine
samples). Analysis of the p70 S6K phoshorylation (probed with an
anti-phosphothreonine 389, which closely correlated with p70S6K
activity that in turn is widely used biological readout for TOR
pathway activation) indicated a greater activity as well as
expression in all transformed cell samples as compared to normal
cell samples. These results well correlate with several observations
from other Authors, highlighting the importance of both Akt and
Figure 7. Cell cycle of synchronized normal and transformed cells released in 0 mM glutamine6dNTPs. Normal and transformed cells,
synchronized by 24 hours of serum starvation, were released in a medium containing 10% serum, 4 mM or 0 mM glutamine, dNTPs and BrdU for
continuous DNA labeling. At indicate time points the cells were collected and stained with propidium iodide and anti-BrdU specific antibody and
analyzed by flow cytometry. The percentages of cells in G1 (panels A and B), S (panels C and D) and G2/M (panels E and F) phase of normal (left
panels) and transformed (right panels) cells released in 4 mM and 0 mM glutamine alone or plus dNTPs obtained by bi-parametric analysis are
represented. The asterisks indicate the S or G2/M phase peaks identified in both glutamine availability. The error bars correspond to standard
deviations of triplicate analysis.
doi:10.1371/journal.pone.0004715.g007
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TOR pathway in the response of normal and transformed cells to
glutamine shortage, the effects of rapamycin (known pharmaco-
logic inhibitor of TOR protein activity) on ability of synchronized
cells to enter in S phase was investigated. We examined whether
adding rapamycin to synchronized normal and transformed cells,
grown both in 4 mM or 0 mM glutamine plus dNTPs, we could
interfere in particular with the execution of G1 to S transition in
transformed cells also in presence of the dNTPs. As shown in
Figure 9A, C and E, normal cell samples, treated with rapamycin,
showed a delay to exit from the G1 arrest (panel A) and, thus a
4 hours delay to reach the S-phase peak (panel C, peaks indicated
by asterisks) and consequently to execute the G2/M transition that
was not observed in the interval of time choose for this specific
experiment (panel E). Transformed cells, released in 4 mM
glutamine plus rapamycin or 0 mM glutamine, showed a slower
exit from G1 arrest and a 4 hours delay to reach the S-phase and
the G2+M peaks (panel D and F, peaks indicated by asterisks) as
compared to 4 mM sample and 0 mM plus dNTPs. Surprisingly,
the sample released in 0 mM glutamine plus dNTPs and treated
with rapamycin, was almost unable to exit from the G1 arrest and
consequently to enter into S-phase. Indeed at later time point
analyzed (18 h), were scored 50% and 34% of cells respectively in
G1 and S phase. These findings were further confirmed by western
blot analysis of cyclin D1 expression. Indeed in both normal and
transformed cells treated with rapamycin the level of expression of
this protein was lower than in untreated samples (data not shown).
Together such results indicate that in normal cells amino acid
deprivation may participate in TOR signalling inhibition inducing
aG 1 arrest, (i.e. by reducing mRNA translation, protein synthesis,
ATP levels and expression of cell cycle regulators), in K-ras
transformed cells such control is deranged by activation of Akt and
by strong inhibition of AMPK, that, acting in a concerted fashion,
maintain also at low or absent glutamine availability a sizable
activity of the TOR pathway, able to promote entrance into S
phase. Indeed, TOR signaling inhibition in synchronized cells
completely block the ability of transformed cells to enter in S phase
also in presence of dNTPs.
Discussion
A genetically defined experimental model in which the
transformed phenotype is phenotypically reverted by expression
of a dominant negative GEF protein that down regulates
oncogenic K-ras [16,17], has allowed us to show in this paper
that glutamine deprivation induces abortive S-phase entrance in
K-ras transformed cells while it does not participate to arrest
normal and reverted cells in G1 phase.
The main results presented in this paper are recapitulated in
Figure 10, in which the metabolic interconnections of glutamine
(Figure 10A) and the effects that glutamine deprivation has on
signaling pathways and molecular events of the G1 to S transition,
both in normal/reverted or in K-ras transformed cells, are
described (Figure 10B and C).
In asynchronous normal cells, contact inhibition, regardless of
glutamine availability, brings to down-regulation of Akt that
together with AMPK up-regulation, observed at low glutamine,
will concur to TOR pathway inactivation. As a result, the
expression of cyclin D, E and A is down regulated, pRb
phosphorylation is strongly reduced, p27
kip1 level is increased
and its localization becomes preferentially nuclear, establishing
therefore a condition that bring to a G1- cell cycle arrest
(Figure 10B). In synchronous normal cells, glutamine shortage
slows the G2/M transition, indicating a possible role of glutamine
in such cell cycle phase.
In K-ras transformed cells, in which the level of activated Ras-
GTP is very high [17] and the contact inhibition is less efficient
[17], the deprivation of glutamine affects Akt and AMPK in a way
opposite to that observed in normal cells, leaving the TOR
pathway at least partially activated (Figure 10C). This event allows
sizable expression of cyclin D (at least until 72 hours), E and A,
sustained pRb phosphorylation, decreased p27
kip1 and its
preferential cytoplasmic localization, conditions that, taken
together, promote entrance into S phase (Figure 10C). In
Figure 8. Activation of AKT, AMPK and TOR pathways in
normal and transformed cells. (A) Time course expression and
phosphorylation of the AKT protein in normal and transformed cell lines
growing in media supplemented with different initial glutamine
concentrations. For the protein expression analysis normal cells and
transformed cells grown in media containing 4 mM glutamine and
0.5 mM glutamine, were collected at appropriate time points and 50 mg
of proteins from the total cellular extract were subjected to SDS-PAGE
followed by Western blotting with a specific anti-phosphorylated
Ser473
AKT (p-AKT) antibody and an anti-AKT (AKT) antibody. (B) Time course
expression and phosphorylation of the AMPKa protein in normal and
transformed cell lines growing in media supplemented with different
initial glutamine concentrations. For the protein expression analysis
normal cells and transformed cells grown in media containing 4 mM
glutamine, 1 mM glutamine and 0.5 mM glutamine, were collected at
appropriate time points and 50 mg of proteins from the total cellular
extract were subjected to SDS-PAGE followed by Western blotting with
a specific anti-phosphorylated
Thr172 AMPK (p-AMPK) antibody and an
anti-AMPK (AMPK) antibody. (C) Time course expression and phos-
phorylation of the S6K protein in normal and transformed cell lines
grown as described in B. Western blotting analysis has been performed
by using a specific anti-phosphorylated
Thr389 S6K (p-AKT) antibody and
an anti-S6K (S6K) antibody. The panels are representative of a triplicate
analysis (Akt and AMPK) or duplicate analysis (S6K).
doi:10.1371/journal.pone.0004715.g008
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G1 to S transition or the G2/M transition.
But why in low glutamine is the S phase of K-ras transformed cells
abortive? Deprivation of glutamine reduces also availability of
nucleotides that leads to a small decrease in RNA accumulation
compared to growth in high glutamine (at least until the 72 hours,
Fig. 5B) and a more dramatic effect on DNA synthesis (Figure 1F,
S1D).Thenotionthatdepletionofdeoxyribonucleotidesisthemajor
effect of glutamine deprivation that leads to reduced proliferation of
transformedfibroblasts,isconfirmedbythefactthattheproliferation
defect of transformed cells is rescued by adding these precursors of
DNA polymerization to low glutamine medium (Figure 6B).
When the low amount of glutamine is still compatible with cell
cycle progression, as in serum starved cells substantially synchro-
nized in G1 (Figure 6), in transformed cells low-glutamine medium
causes a 2 hours delay in entering into S-phase after serum re-
addition. The same delay is transmitted to the G2/M transition,
indicating that no major compensatory mechanism on cell cycle
timing between completion of S-phase and cell division are
operative. This effect on cell cycle timing is worsened by complete
absence of glutamine (Figure 7), in which 4 hours delay in entering
into S-phase and in the execution of G2/M transition have been
observed. These data strongly indicate that the effect of glutamine
limitation in transformed cells is first to slow down the S-phase
traverse, then, when a more severe limitation is established, to
stuck a large fraction of the cells population in S phase.
Studies performed in several cellular models have shown that
availability of dNTPs and therefore the regulation of their
Figure 9. Analysis of cell cycle upon rapamycin treatment. Normal and transformed cells, synchronized by 24 hours of serum starvation, were
released in a medium containing 10% serum, 4 mM glutamine6Rapamycin or 0 mM glutamine6Rapamycin and6dNTPs and BrdU for continuous
DNA labeling. At indicate time points the cells were collected and stained with propidium iodide and anti-BrdU specific antibody and analyzed by
flow cytometry. The percentages of cells in G1 (panels A and B), S (panels C and D) and G2/M (panels E and F) phase of normal (left panels) and
transformed (right panels) cells, released in the mediums indicated above, and obtained by bi-parametric analysis are represented. The asterisks
indicate the S or G2/M phase peaks identified in both glutamine availability. The error bars correspond to standard deviations of triplicate analysis.
doi:10.1371/journal.pone.0004715.g009
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PLoS ONE | www.plosone.org 13 March 2009 | Volume 4 | Issue 3 | e4715Figure 10. A model of the role of glutamine in controlling the G1/S transition. In the panels the following convention are used. Metabolic
connections are indicated by black arrows. Blue lines indicate positive (arrowhead) or negative (blunt end) regulatory connections. Up- and down-
regulation are indicated by red arrows pointing either upwards or downwards, respectively. A full block is indicated by a red X, a leaky block by a
dotted X. (A) Some metabolic roles of glutamine are represented within a light blue area. (B) Summary of events originating from glutamine shortage
in asynchronous and synchronous normal cells. Biological readouts of proteins involved in the G1 to S transition and the effects on cell cycle are
reported. (C) Summary of events originating from glutamine shortage in asynchronous and synchronous K-ras transformed cells. Biological readouts
of proteins involved in the G1 to S transition and the effects on cell cycle are reported.
doi:10.1371/journal.pone.0004715.g010
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expression of dNTP synthetic enzymes is cell cycle-regulated, with
enhanced expression at the onset of S-phase [50,51]. Additionally,
dNTP levels vary within S-phase of the cell cycle [52] thereby
changing the rate of DNA replication during S-phase [53]. Even
subtle changes in the levels of dNTPs may have a sizable effect on
DNA replication [54]. Nucleotide depletion, obtained through
chemical inhibition of their biosynthesis, may induce either G1 or
S-phase arrest or slow down the overall progression of S-phase
[55,56]. Addition of a mix of 10 mM deoxyribonucleotides
reverted effects on both asynchronous and asynchronous cultures
indicating that the earlier and major rate-limiting step dependent
on glutamine-deprivation pathway is connected with nucleotide
biosynthesis. Nevertheless, such connections appear to be lost
both in asynchronous and synchronous cells when a complete
limitation of glutamine in the culture medium occurs. Indeed at
later time points of low glutamine proliferation curve of
transformed cells (72–96 h), corresponding to almost a complete
depletion of glutamine in the culture medium (Figure S2B),
dNTPs are not more able to restore the proliferation (Figure 6B)
indicating that in such condition other cellular responses are
activated by glutamine depletion. Furthermore in transformed
synchronous cells, released in complete glutamine depleted
medium, dNTPs are able to restore the S-phase transition but
not the proper time of execution of G2/M phase (Figure 7F).
Indeed such cell cycle phase was delayed as well as observed in the
sample without glutamine and dNTPs. Other Authors have
observed this result in different cell lines. For instance, Abcouwer
et al. [57], showed that reduction of glutamine availability in the
growth medium of several breast cancer cells might induce
GADD45 and GADD153 expression by mRNA stabilization.
GADD45 overexpression has been shown to induce G2/M cell
cycle arrest [58] following several environmental stresses.
Moreover, Drogat et al. [38], showed that in A549/8 carcinoma
cells glutamine deprivation decreased the number of cells in the
G1 phase, transiently increased that of cells in the S phase, and
induced a stable increase in cell number in the G2/M phase.
These findings may explain the delay to reach the G2/M peak
observed in both normal and transformed cells released in low or
complete absence of glutamine (Figure 6 and 7).
In cells exhibiting high metabolic rates, such as rapidly dividing
cancer cells grown in vitro, glutamine, being the most readily
available amino acid used as energy source, may became the
major source of energy to sustain protein and nucleic acid
synthesis [11], especially when glucose levels are low and energy
demand is high. A correlation between glutamine depletion and
decreased level of Krebs cycle intermediates in myc-transformed
cells has been identified [35].
In our system metabolic readouts of transformed cells -
including ATP, RNA and protein levels - are quite close to those
found in normal and reverted cells. Addition of Krebs cycle
intermediates has no effect on K-ras transformed fibroblasts
(Figure 5 and S5) thereby suggesting that proliferation arrest
may be independent on Krebs cycle intermediates depletion and
energy shortage. On the contrary, we showed that ATP drops in
the same cell lines grown under limiting glucose availability, linked
to inability of these cells to properly activate mitochondrial
respiration [14,15], eventually leading to cell death. Such partial
derangement of mitochondrial function is further confirmed in the
present report, since we show that K-ras transformed cells grown in
a medium in which glucose was completely replaced by 1 mM
pyruvate and 4 mM glutamine, substrates used essentially for
Krebs cycle and oxidative respiration, grow poorly (Figure S7) and
eventually die (data not shown).
In conclusion, glutamine shortage in K-ras transformed cells
limits proliferation by inducing abortive S-phase entrance, while
glucose shortage in the same system enhanced cell death [14,15].
The differential effects of glutamine and glucose on cell viability
are not a property of the transformed phenotype per se, but rather
depend on the specific pathway being activated in transformation.
For instance, myc-overexpressing cells die under complete
glutamine depletion in a myc-dependent way and not under
glucose depletion [35]. In the same experimental conditions,
complete glutamine depletion, cell death of K-ras transformed cells
die is marginal compared to that observed in myc-overexpressing
cells (data not shown). These different responses of transformed
cells to nutritional stress should be taken into account when
designing anti-cancer therapies that aim to exploit metabolic
differences between normal and transformed cells.
Materials and Methods
Cell culture
Mouse embryonic fibroblast NIH3T3 cells (CRL-1658; Ameri-
can Type Culture Collection) and a K-Ras transformed NIH3T3-
derived cell line, 226.4.1 [59], were routinely grown in Dulbecco’s
modified Eagle’s medium containing 10% newborn calf serum,
4 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml strepto-
mycin (normal growth medium) (all from Invitrogen, Carlsbad, CA,
USA) at37uCina humidified atmosphere of5%CO2.Thereverted
cell line, stably and constitutively expressing the dominant negative
mutant Cdc25
MmW1056E (GEF-DN) [17] was maintained in normal
growth medium supplemented with 0.7 mg/ml geneticin (G418;
Sigma-Aldrich Inc., St. Louis, MO, USA). Cells were passaged
using trypsin-ethylenediaminetetraacetic acid (EDTA) (Invitrogen)
and maintained in culture for 48 h before manipulation.
Cell treatments
To verify cell response to glutamine, cells were plated at 3000
cells/cm
2 in normal growth medium (4 mM Glutamine). 18 h
after seeding, cells were washed 26with phosphate-buffered saline
(PBS) and incubated in media with different glutamine (GLN)
concentrations (4 mM, 1 mM and 0.5 mM glutamine). When
required, 2 mM pyruvate (Sigma), 2 mM malate (Sigma), 10 mM
dNTPs (Rovalab), and 20 nM rapamycin (ALEXIS Biochemicals),
were added as indicated in the text.
Cell synchronization
Cells were plated at 5500 cells/cm
2 in normal growth medium.
18 h after the seeding, cells were washed 26 with PBS and
synchronized by 24 h of serum starvation with Dulbecco’s
modified Eagle’s medium containing 4 mM L-glutamine,
100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen),
6 ng/ml sodium selenite and 6 mg/ml transferrin (Sigma).
Stimulation of quiescent cells was performed by adding 10%
newborn calf serum in medium with the appropriate glutamine
(and dNTPs, when required) concentration. DNA was labelled
with 33 mM 5-Bromodeoxyuridine.
Flow cytometric analysis
The distribution of cells at specific cell cycle phases was evaluated
by flow cytometry. Cells were trypsinized, washed with PBS and
fixed in 75% ethanol at 4uC. The cells were washed in PBS for
ethanol removal and incubated for 30 min in 0.25% Triton X-100
and HCl 2N. Subsequently, each sample was stained with an anti-
BrdUprimaryantibody(Becton-Dickinson)for1 h,andprobed with
Alexa Fluor 488 donkey anti-mouse IgG (Molecular Probes/
Invitrogen) to identify S-phase. In addition, the same samples were
Glutamine Oncogenic Kras Cells
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(FACScan, Becton-Dickinson), using the Cell Quest software (BD
Bioscience). Data analysis was performed with WinMDI software.
Glutamine assay
Glutamine variation in supernatants of normal and transformed
fibroblasts was determined by using a spectrophotometric
glutamine/glutamate enzyme assay kit (Sigma) based on enzy-
matic deamination of L-glutamine and dehydrogenation of L-
glutamate with conversion of NAD
+ to NADH. The assay was
performed as specified by manufacturer datasheet and it is specific
for glutamine and does not cross-react with other amino acids or
ammonia. To calculate the quantity of glutamine a linear
regression analysis of the standard curve was performed.
Immunofluorescence microscopy
Cells were grown on coverslip previously treated with 0.2%
gelatine. The cells were washed 36 with PBS and fixed in 4%
paraformaldehyde in PBS for 10 min. Subsequently, were washed
36with PBS, permeabilized with 0.1% Triton X-100 for 10 min,
blocked with PBS+10% goat serum for 30 min, probed with
primary antibody p27
kip1 (1:100) (Santa Cruz Biotechnology CA,
USA) in PBS+10% goat serum for 1 h at room temperature,
washed 36with PBS, probed with fluorescence-labeled secondary
antibody Alexa Fluor 594 goat anti-rabbit IgG (1:400) (Molecular
Probes/Invitrogen) in PBS+10% goat serum for 30 min at room
temperature, washed 36with PBS, stained with DAPI for 2 min
(1:500) (Sigma-Aldrich Inc), and then mounted in DABCO
(Sigma-Aldrich Inc). For BrdU (Sigma-Aldrich Inc.) labeling, cells
were fixed, permeabilized and blocked as described above. After
the cells were incubate with an anti-BrdU monoclonal antibody
(1:10) (Becton-Dickinson), MgCl2 (3 mM) and DNasi I (Invitrogen)
100 U/ml for 1 h at RT. Subsequently, the cells were washed 36
with PBS and incubated with fluorescence-labeled secondary
antibody Alexa Fluor 488 donkey anti-mouse IgG (1:100)
(Molecular Probes/Invitrogen) in PBS+10% goat serum for
30 min at room temperature, washed 36with PBS, stained with
DAPI for 2 min (1:500) and then mounted in DABCO.
Microscopy
The cover glasses, mounted in DABCO, were analyzed under a
Nikon ECLIPSE 90i fluorescence microscope equipped with a b/
w CCD camera (Hamamatsu-CoolSNAP, Hamamatsu Corpora-
tion Japan), using Plan Apo objective (406 dry and 606 oil;
numerical aperture 0.75 and 1.4 respectively). The images were
acquired using the imaging software Metamorph 7, then processed
in Adobe Photoshop 7.0.1 with adjustments of brightness and
contrast. The quantitative analysis image was performed using the
imaging software Image J. The relative distribution of p27
kip1
protein between the two compartments nucleo/cytoplasm, was
calculated by measuring the pixel average signal both in the
nucleus, cytoplasm and nucleo/cytoplasm compartments. At least
200 cells, together with negative controls (no primary antibody),
were randomly selected. In order to exclude the background of
staining and to select the positive stained parts of the cells for
measurement, the images from the various samples were processed
at the same threshold and then measured.
Immunoblot analysis
Cells were lised in a buffer containing 150 mM NaCl, 0.5% NP-
40, 1% glycerol, 50 mM HEPES (pH 7.5), 5 mM ethyleneglycol
tetracetate (EGTA), 1 mM phenylmethylsulphonyl (PMSF),
50 mM NaF and a cocktail of protease inhibitors (Roche). After
incubation for 30 min on ice, the extracts were centrifuged at
13.200 r.p.m. for 20 min. Protein concentration of supernatant
was measured by the Bradford procedure (Bio-Rad Laboratories,
Richmond, CA, USA), using bovine serum albumin as a standard.
These cellular extracts were electrophoresed in sodium dodecyl-
sulfate (SDS) polyacrylamide gels. After electrophoresis, the
proteins were transferred to nitrocellulose membrane by electro-
blotting and incubated with antibodies over night.
The antibodies used were monoclonal or polyclonal antibodies
against cyclin D1, cyclin E, cyclin A, p27
Kip1, Cdk2, Cdk4 (all from
Santa Cruz Biotechnology), phosphoRb-795, p70 S6 kinase,
phospho-p70 S6 kinase and vinculine (all from Cell Signalling).
Subsequently, the membranes were incubated with a peroxidase-
coupled secondary antibody (Amersham, Othelfingen, CH) for
30 min at room temperature. The reaction was visualized with ECL
(Amersham) followed by exposure to an x-ray film. Protein
expression levels were quantified by densitometric evaluation of
antibody specific bands on scanned x-ray films by using the imaging
software Image J.
RNA extraction and analysis
Total RNA was isolated from normal and transformed cell lines
using TRIzol reagent (Invitrogen). RNA purity and integrity were
checked by direct observation loading 1 mg of total RNA on 1%
agarose gel. Total RNA had a 28S:18S rRNA ratio of at least 2.0.
Amount estimation was done by spectrophotometer analysis.
Supporting Information
Figure S1 Analysis of glutamine concentration, along a time
course of 96 h, of normal (blue diamond) and transformed (red
square) cells plated in 4 mM (A) and 0.5 mM (B) initial glutamine
availability.
Found at: doi:10.1371/journal.pone.0004715.s001 (1.25 MB TIF)
Figure S2 Proliferation and cell cycle analysis of lower density
plated cells.
Found at: doi:10.1371/journal.pone.0004715.s002 (8.16 MB TIF)
Figure S3 Cdk2 and Cdk4 proteins expression is more stable in
transformed cells.
Found at: doi:10.1371/journal.pone.0004715.s003 (1.56 MB TIF)
Figure S4 p27kip1 localization in BrdU positive cells and
p21waf1 expression in normal and transformed cells.
Found at: doi:10.1371/journal.pone.0004715.s004 (2.65 MB TIF)
Figure S5 Glutamine availability effect on total cellular proteins
as detected by Gel-Code Blue Comassie staining.
Found at: doi:10.1371/journal.pone.0004715.s005 (4.43 MB TIF)
Figure S6 Proliferation ability and time of re-entry upon serum
starvation and release in cells grown in 4 mM glutamine.
Found at: doi:10.1371/journal.pone.0004715.s006 (2.68 MB TIF)
Figure S7 Glucose depletion induces a strong cell proliferation
arrest in K-ras transformed mouse fibroblasts.
Found at: doi:10.1371/journal.pone.0004715.s007 (1.15 MB TIF)
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